ARICEPT, AN ALZHEIMER'S DISEASE TREATMENT, RECEIVES PRODUCTION APPROVAL IN JAPAN
Tokyo (October 12, 1999) - Eisai Co., Ltd. of Tokyo (President and CEO: Haruo Naito) today announced that the Alzheimer's disease treatment, ARICEPT (generic name: donepezil hydrochloride) has received production approval for 3 mg and 5 mg formulations from the Japanese Ministry of Health and Welfare. After receiving a National Health Insurance (NHI) Price, ARICEPT 3 mg, and ARICEPT 5 mg, will be copromoted in Japan with Pfizer Pharmaceuticals under a one brand one channel sales structure with Eisai recording sales.
Alzheimer's disease is a progressive form of dementia with symptoms of memory loss, behavioral changes and eventual loss of language and motor skills.
ARICEPT inhibits acetylcholinesterase, an enzyme which breaks down the neurotransmitter acetylcholine, associated with memory and learning, thereby allowing a greater concentration of acetylcholine in the brain. ARICEPT is expected to improve cognition and prevent the progression of symptoms in people with mild to moderate Alzheimer's disease.
ARICEPT is a new reversible acetylcholinesterase inhibitor synthesized by Eisai in Japan, with sales first beginning in the U.S. and currently ARICEPT is being sold in 41 countries worldwide (as of September 30,1999).
isai Co., Ltd. is a research-based human health care company which discovers, develops and markets products in more than 30 countries. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide health care system. The company reported sales of over $2.3 billion in 1998 with greater than 15 percent of sales spent for research and development.
ARICEPT is a trademark of Eisai Co., Ltd.
ARICEPT Product Outline